Full-Life Sciences Breaks Ground on GMP Radiopharmaceutical Manufacturing Facility in Gembloux, Belgium, Advancing Its End-to-End Radiopharmaceutical Solutions

December 8, 2023, Jambes, Belgium: Full-Life Technologies Limited (“Full-Life Technologies”), a fully integrated international radiopharmaceutical therapy company, announced today the commencement of construction on its Good Manufacturing Practice (“GMP”)-compliant radiopharmaceutical production facility in Jambes, Belgium. This strategic investment aims to establish radiopharmaceutical production capabilities in a key logistics hub, thereby advancing Full-Life Technologies’ end-to-end industry chain solutions and ensuring timely delivery of medicines to patients worldwide. A groundbreaking ceremony was held to commemorate this milestone.

Mr. Philippe van Put, General Manager of Full-Life Technologies in Europe, stated: “Today marks a significant milestone in Full-Life Technologies’ evolution into a fully integrated radiopharmaceutical company, underscoring our commitment to excellence and innovation in the field of radiotherapy. Effective manufacturing and supply chain management are critical to the development and commercialization of radiopharmaceuticals. This facility will ensure a stable supply for our clinical development programs, while the location in Blois provides us with unique advantages, as the city lies at the heart of Europe’s biotechnology innovation corridor, boasting a rich pool of expertise and a robust logistics network.”

Mr. van Put added, “We would also like to express our gratitude to the Walloon Regional Government for their cooperation and support in creating a favorable environment for the development of the radiopharmaceutical industry.”

Spanning 4,000 square meters, this advanced facility will serve as the production center for Full-Life Technologies, combining eco-friendly and sustainable design with automated and digital quality assurance systems. At its operational core is the commitment to ensuring supply chain controllability and reliability, while achieving cost reduction and efficiency improvement. Situated on a 17,000-square-meter plot, the facility is dedicated to the production of a diverse range of radiopharmaceuticals.

The groundbreaking ceremony brought together industry experts, healthcare professionals, community leaders, and investors to celebrate the official commencement of construction by Full-Life Technologies in Jambes, marking a significant milestone for the company.

Full-Life Technologies Limited (“Full-Life Technologies”) is a fully integrated, international radiopharmaceutical therapy company with offices in Belgium, Germany, and China. We are committed to building a nuclear medicine company with a complete industry chain encompassing the research and development, manufacturing, and commercialization of radiopharmaceuticals, thereby benefiting patients worldwide. We plan to address the core challenges currently affecting radiopharmaceutical R&D through innovative research focused on future therapeutic approaches. Our team comprises seasoned entrepreneurs and scientists who excel not only in managing biopharmaceutical companies but also possess deep expertise in the research and clinical development of radioisotopes.